02:49 PM EST, 01/23/2026 (MT Newswires) -- CVRx ( CVRX ) shares rose 12% in recent trading on Friday after the company said it started its clinical trial to evaluate the impact of the Barostim implantable device in a significantly expanded heart failure population.

The trial's primary endpoint will be a composite of all-cause mortality and heart failure decompensation events, CVRx ( CVRX ) said. If successful, the trial has the potential to expand the indicated patient population for Barostim by about three times, broadening access to heart failure management, the company added.

Enrollment is expected to begin in H1, with further details to be provided in CVRx's ( CVRX ) earnings call in February, the company said.

Price: 7.40, Change: +0.84, Percent Change: +12.80